



• Dermatology  
beyond the skin

# **SPONSORSHIP AGREEMENT**

**BETWEEN**

**LEO Pharma A/S**

**and**

**Eksemforeningen**

**TABLE OF CONTENTS**

1. **PURPOSE** ..... 3

2. **OBLIGATIONS OF THE PARTIES** ..... 3

3. **PLACE AND TIME**..... 4

4. **FINANCIAL COMMITMENT** ..... 4

5. **NON-FINANCIAL COMMITMENT** ..... 5

6. **TRANSPARENCY** ..... 5

7. **USE OF THE ORGANIZATION’S LOGO OR THE LEO PHARMA LOGO**..... 6

8. **INDEPENDENCE AND CONFLICT OF INTEREST** ..... 6

9. **ANTI-BRIBERY AND THIRD PARTY COMPLIANCE**..... 6

10. **FORCE MAJEURE** ..... 7

11. **TERM AND TERMINATION**..... 7

12. **LAW AND VENUE**..... 7

13. **SIGNATURES AND COMPLETENESS OF THE AGREEMENT**..... 8

**LIST OF SCHEDULES**

SCHEDULE A:	REQUEST LETTER
SCHEDULE B:	BUDGET

This Sponsorship Agreement (the “**Agreement**”) effective as of the date of the last signature on the Agreement (the “**Effective Date**”) is made and entered into by and between:

- (1) **LEO Pharma A/S**, a company organised and existing under the laws of Denmark and having its registered office at Industriparken 55, 2750 Ballerup, Denmark, with its company registration no. 56759514 (“**LEO Pharma**”), and
- (2) **Eksemforeningen**, an organization existing under the laws of Denmark and having its registered office at Hvidovrevej 108, 1. tv., 2650 Hvidovre, Denmark with registration no. 33736665 (the “**Organization**”),

LEO Pharma and the Organization hereinafter each referred to as a “**Party**” and collectively referred to as the “**Parties**”.

**WHEREAS:**

- (A) LEO Pharma is a research-based pharmaceutical company that develops, manufactures and markets pharmaceutical products to patients within dermatology and thrombosis;
- (B) The Organization is a working with supporting, education and information for patients and caregivers diagnosed with Atopic Dermatitis
- (C) The Organization has requested support from LEO to support the project as listed in schedule A;
- (D) LEO Pharma agrees to support the Organization to increase awareness, put focus and attention on Atopic Dermatitis as described in schedule A

NOW THEREFORE, the Parties have agreed as follows:

**1. PURPOSE**

- 1.1. The purpose of this Agreement is to describe the terms and conditions for the funding to provide economic support made by LEO Pharma to the Organization in connection with the request to support the project and initiative for children living with AD and their families, as described in Schedule A (“**Project**”).

**2. OBLIGATIONS OF THE PARTIES**

- 2.1. LEO Pharma undertakes during the term of the Agreement to provide Funding to the Project.
- 2.2. The Organization has provided LEO Pharma with a request letter (attached as **Schedule A**) and a full breakdown of the

Project budget (attached as **Schedule B**), to be covered by the Funding from LEO Pharma.

- 2.3. The Organization represents and warrants to comply with any and all applicable laws, regulations and industry ethical codes in force from time to time in connection with the Project including, but not limited to, the codes listed in Clause 2.4.
- 2.4. The Organization acknowledges that LEO Pharma must comply with applicable industry ethical codes including but not limited to:
  - the International Federation of Pharmaceutical Manufactures and Associations (IFPMA) Code of Practice;
  - The European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice
  - the Danish Ethical Committee for the Pharmaceutical Industry's (ENLI) Code of Practice on Promotion etc., of Medicinal Products aimed at Healthcare Professionals (Reklamekodekset)
  - the Danish Ethical Committee for the Pharmaceutical Industry (ENLI) Ethical Rules for Collaboration between Patient Organizations, etc., and the Pharmaceutical Industry; and
  - any other applicable national industry Code of Practice regarding the relationship between the pharmaceutical industry and healthcare professionals ("HCPs") and/or healthcare organizations ("HCOs");
- 2.5. The Organization undertakes to ensure that the Funding received from LEO Pharma will be spent solely in connection with the Project, in a reasonable manner and in accordance with this Agreement and the ethical codes listed in Clause 2.4. The Funding must solely be spent on the professional/scientific activities of the Project. This entails, inter alia, that the Organization confirms that all elements of the Project, for example the venue, are reasonable and in no way extravagant. The Organization also confirms that no elements of entertainment are contained in the Project and that no gifts will be provided to the participating healthcare professionals during the course of the Project.
- 2.6. Any unused portion of the Funding must be returned to LEO Pharma within thirty (30) days of finalisation of the Project. Upon request from LEO Pharma the Organization must provide documentation for the paid expenses in relation to the Project.
- 2.7. The Organization confirms that it has obtained and will maintain all consents and permissions necessary to conduct its business including the Project.

### **3. PLACE AND TIME**

- 3.1. The Project takes place in Denmark from December 15, 2025, to December 20 2026.

### **4. FINANCIAL COMMITMENT**

- 4.1. The financial commitment of LEO Pharma under this Agreement shall be 100.000 DKK (the "**Funding**"). The amount is exclusive of VAT.
- 4.2. The Organization shall contact LEO Pharma immediately if any circumstances, including as set out in **Schedule A**, change

and LEO Pharma reserves the right to withdraw the Funding if the Project is changed or cancelled prior to completion. The Organization shall return any unused portion thereof, to LEO Pharma within thirty (30) days after of such withdrawal.

- 4.3. The Organization have engaged external consultancy company Molecule Consultancy (Molecule Consultancy A/S. c/o Rebel Work Space, Dampfærgevej 27-29, 5. Sal. 2100 København Ø. CVR 28 51 57 66) and they issue an invoice to LEO Pharma A/S, Att: Kristin Fauskrud, Industriparken 55, 2750 Ballerup, Denmark. Invoice must be sent as a PDF file to knfno@leo-pharma.com, marked "Att: Kristin Fauskrud Eksemforeningen – Patient empowerment 2026" in the subject line. The invoice must be sent no later than fifteen (15) days after the signature of this Agreement.

The invoice shall include following information:

- LEO Pharma A/S VAT no: DK 56759514
- Full name and address of Organization
- Invoice number and date
- Name of Project
- Invoice currency
- Bank details
- Organization VAT number
- If the Funding is subject to VAT or any other local taxes, any mandatory data in accordance with the provisions of the applicable VAT or tax laws.

Payment terms are end of month plus thirty (30) days from receipt of invoice by LEO Pharma.

## **5. NON-FINANCIAL COMMITMENT**

- 5.1. LEO Pharma will not provide any non-financial commitment under this Agreement.

## **6. TRANSPARENCY**

- 6.1. The Organization must ensure that the receipt of the Funding from LEO Pharma is acknowledged and disclosed in accordance with all applicable laws, regulations and industry ethical codes, including, but not limited to, the codes listed in Clause 2.4. This entails, inter alia, that the Organization shall ensure that (a) the organiser and purpose of the Project appears from the invitation, including any updates to the invite or reminders, to the Project sent out by the Organization, and (b) the invitation states whether the Project has been sponsored by one or more pharmaceutical companies.
- 6.2. The Organization shall publish information that LEO Pharma has provided the Funding on the Organization's website at the latest three (3) days after signing this Agreement.
- 6.3. The Organization accepts that LEO Pharma may notify relevant authorities about the content of this Agreement and publish

information regarding this Agreement and the Funding of the Project on the LEO Pharma company website in accordance with applicable laws, regulations and industry ethical codes.

- 6.4. The Organization acknowledges that LEO Pharma and its affiliates, may be required by applicable law, regulation and industry codes, to report, register, disclose and/or publish information about the relationship of the Parties (including any identified indirect recipient of the Funding), payments and/or other transfer of value made to the Organization by or on behalf of LEO Pharma or its affiliates under this Agreement.

## **7. USE OF THE ORGANIZATION'S LOGO OR THE LEO PHARMA LOGO**

- 7.1. The Organization agrees that LEO Pharma may use the Organization's logo or name, and make use of the collaboration with the Organization. Any other use of the Organization's logo must be approved beforehand by the Organization.
- 7.2. LEO Pharma agrees that the Organization may use LEO Pharma's logo or name and make use of the collaboration with the Organization for the purposes mentioned in Clause 6.2. Any other use of the LEO Pharma logo must be approved beforehand by LEO Pharma.

## **8. INDEPENDENCE AND CONFLICT OF INTEREST**

- 8.1. The Parties declare by signing this Agreement that the Organization shall be free to collaborate with other pharmaceutical companies and that LEO Pharma shall be free to collaborate with other Organizations. The Parties further state that their relations shall not involve exclusive rights with respect to specific product or therapeutic areas.
- 8.2. LEO Pharma shall not influence the content of the Project and the organization of the Project is independent of the Funding.
- 8.3. LEO Pharma agrees by signing this Agreement not to impose conditions for the Organization's professional or stakeholder-policy viewpoints. This Agreement shall not be seen as an explicit or implicit agreement that confer an obligation on the Organization to recommend, induce, ordinate, purchase, deliver, sell, administer or in any other way promote the interest of LEO Pharma or its products.

## **9. ANTI-BRIBERY AND THIRD PARTY COMPLIANCE**

- 9.1. The Organization acknowledges that LEO Pharma is committed to maintaining high standards of ethical conduct and will not tolerate the use of bribery or corruption to achieve its business objectives. Thus, the Organization agrees to comply at all times with all applicable anti-bribery laws, rules and regulations (including the UK Bribery Act and the United States Foreign Corrupt Practices Act) when performing its duties under this Agreement.

9.2. The Organization and its representatives shall at all times conform to the Sustainability Standards for LEO Pharma Business Partners (“**Sustainability Standards**”) as amended from time to time. The latest effective version of the Sustainability Standards are available at [www.leo-pharma.com/thirdparty](http://www.leo-pharma.com/thirdparty). Upon request, the Organization shall provide information on its level of compliance with the Sustainability Standards so that LEO Pharma can assess whether the Organization actually complies with these. The Organization shall at all times and promptly take all appropriate steps to resolve and correct any identified non-conformity. Any breach of Clauses 9.1-9.2 is considered material and shall, without limiting any other right or remedy available, entitle LEO Pharma to terminate this Agreement in whole or in part with immediate effect.

## **10. FORCE MAJEURE**

10.1. Either Party shall be excused from performing its obligations under this Agreement if its performance is delayed or prevented by any cause beyond such Party’s reasonable control and which could not have reasonably been foreseen by such Party on the date on which the Party undertook its obligations. Relevant causes for excuse include, without limitation, terrorist acts, fires or explosions, civil strifes, riots, natural disasters, strikes and labour disturbances at national level or generally including labour not employed by the affected Party, wars, hostilities (whether war be declared or not), sabotages, embargos or government actions. Performance shall be excused only to the extent of and during the reasonable continuance of such disability.

## **11. TERM AND TERMINATION**

11.1. This Agreement shall come into force on the day of the last signature to the Agreement and shall, unless terminated earlier, remain in force until the Project has been completed which date the Agreement shall be terminated automatically.

11.2. If the Organization breaches any of its obligations under this Agreement, LEO Pharma may terminate the Agreement with immediate effect and be entitled to seek other legal redress under Danish law for breach of agreement, including a claim for compensation irrespective of whether the Agreement has been terminated.

11.3. Upon expiration or termination of this Agreement for any reason Clauses 6, 9 and 11 and such other Clauses that by their nature are intended to survive termination, shall survive the termination of this Agreement.

## **12. LAW AND VENUE**

12.1. This Agreement shall be governed by the laws of Denmark without regard to the conflict of laws provisions.

12.2. In the event of any dispute arising out of or relating to any provision of this Agreement, the Parties shall try to settle any such dispute amicably on a good faith basis. If the Parties are unable to solve the dispute within reasonable time, the dispute shall be brought before the city court of Glostrup, Denmark, as the court of first instance.

### 13. SIGNATURES AND COMPLETENESS OF THE AGREEMENT

13.1. This Agreement constitutes the entire agreement between the Parties relating to the Project and no other express terms, written or oral, shall be incorporated into this Agreement. In case of any contradictions between this Agreement and any of its schedules, this Agreement shall prevail.

13.2. The Agreement may be executed in one or more counterparts, each of which shall be an original and all of which shall constitute together the same document. The Parties agree that the execution of this Agreement by standard industry signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures.

Accepted and agreed:

#### Eksemlforeningen

#### LEO Pharma A/S

Date: \_\_\_\_\_

Date: \_\_\_\_\_

Signature: *Anne Skov Vastrup*  
Digitalt underskrevet af Anne Skov Vastrup  
Årsag: Accepteret og Enig  
Dato: 2025-11-26 12:00:28+01:00

Signature: *Anja Verhaug*  
Digitally signed by Verhaug, Anja Cecilie  
Reason: Accepteret og Enig  
Date: 2025-11-26 12:50:55+01:00

Name: Anne Skov Vastrup

Name: Anja Verhaug

Title: Formand

Title: General Manager Nordic

## Schedule A – Request Letter



LEO Pharma A/S  
Industriparken 55  
2750 Ballerup  
Att.: Kristin Fauskrud  
KNFNO@leo-pharma.dk

S

Kokkedal den 13. november 2025

### Anmodning om støtte til "Patient empowerment og eksemquiz"

Eksemforeningen har modtaget 100.000 kr. fra Udlodningsmidlerne til opgradering af hjemmesiden, hvilket gør det muligt for os at forbedre patientoplevelsen på hjemmesiden og sikre alle besøgende en bedre oplevelse og relevant information ved besøg hos os. I forlængelse af dette ønsker vi at forbedre og optimere patientoplevelsen ved at indføre mulighed for en "quiz-rundtur", når man besøger os. I stil med den quiz, man kan tage, når man besøger hovedpineforeningen.dk

Formålet er at sikre alle patienter relevant information og viden om, hvad man kan forvente med hensyn til at være velbehandlet – altså call-to-action, indtil man når dertil.

Vi har i samarbejde med Molecule Consultancy lavet et legoklods-budget for opdatering af fagligt indhold via artikler (ca. 22.000 kr. før moms pr. område), udvikling og implementering af quiz (ca. 140.000 kr. før moms), lancering af det hele (ca. 124.000 kr. før moms) samt opfølgende og uddannende email-program (ca. 87.000 kr. før moms).

### Økonomisk anmodning

Vi søger støtte hos både AbbVie, Almirall, LEO Pharma, Galderma og Sanofi, og i forhåbning om at fire selskaber har lyst og mulighed for at bakke op, anmoder vi LEO Pharma om 100.000 kr. til projektet.

Vi håber, at I kan bevillige 100.000 kr. før moms til projektet, hvor vi gerne vil lade Molecule Consultancy administrere budgettet samt stå for fakturering.

På forhånd mange tak for opbakningen til foreningens arbejde.

Mange hilsner fra  
Anne Skov Vastrup, forperson i Eksemforeningen

### BILAG

- Patient empowerment og Eksemquiz projekt og budget

Eksemforeningen · Lone Grøn Laursen · Hvidovrevej 108, 1. tv. · 2650 Hvidovre  
info@eksemforeningen.dk · eksemforeningen.dk  
Facebook Eksemforeningen · Facebook-gruppe Eksemforeningen · LinkedIn Eksemforeningen

Schedule B – Budget

Artikler	EX moms	Inkl. moms
<p><b>Behandling af eksem, inkl. ikoner</b>                      Guide til de forskellige behandlingsmuligheder ved eksem fra hormoncremer til målrettede behandlinger                      Inkl. design af op til 10 illustrative ikoner, der visualiserer og forklarer behandlingsmuligheder mm. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	37.200	<b>46.500</b>
<p><b>Behandlingstrappen og hvem kan hjælpe, inkl. illustration</b>                      Oversigt over, de tre typer læger, der kan hjælpe med eksem og en forklaring af, hvornår, man skal videre i behandlingssystemet, understreget af den eksisterende speed drawing og kvikguide.                      Inkl. design af behandlingstrappen for at tydeliggøre de tre niveauer i behandlingen. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	24.800	<b>31.000</b>
<p><b>Hvad vil det sige at være velbehandlet?</b>                      Afklaring af, hvornår du er i mål med en behandling. Artiklen skal empower eksemramte til at blive ved med at søge (ny) behandling, til de er blevet (næsten) eksemfrie – for det er i dag muligt. Dette for at eksemramte ikke giver op undervejs – eller vænner sig til symptomerne og tror, det ikke kan blive bedre. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	21.200	<b>26.500</b>
<p><b>Sammenhængen mellem eksem og andre sygdomme</b>                      Forklaring af, hvorfor mange med eksem også lider af astma og allergi, og hvordan flere sygdomme er forbundne, kan påvirke hinanden og evt. have betydning for behandlingen. Inkl. illustration, der viser sammenhængen, sundhedsfaglig validering, indkøb af foto og opsætning.</p>	22.400	<b>28.000</b>
<p><b>Q&amp;A om eksem</b>                      Spørgsmål/svar på, hvad atopisk eksem er, årsager, hyppighed, hvorfor det klør og ikke mindst budskabet om, at det er muligt at gøre noget ved. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	23.600	<b>29.500</b>
<p><b>Barn med eksem (mårettet familien)</b>                      Råd til forældre til børn med eksem, både om behandling og nødvendigheden af den og om gode råd til indsmøring, kløe og hverdagen med et eksembarn. Deler også foreningens eksisterende familiefilm og animationsfilm om, hvordan du hjælper dit barn med eksem. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	22.400	<b>28.000</b>

<p><b>Ung med eksem</b> Råd til unge, der står over for selv at skulle tage ansvaret for deres eksem og behandling af det. Guider til, hvordan man får hjælp til eksem, inkl. eksisterende animationsfilm. Deler tips fra andre unge om makeup, fashion, fester, dating og intimitet. Deler også foreningens eksisterende videoer og podcast med unge med eksem. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	22.400	<b>28.000</b>
<p><b>Voksen med eksem</b> Råd til voksne, der stadig kæmper med eksem. Målet er at give dem troen på, at det kan blive bedre, bl.a. ved at dele eksisterende patientfilm med voksne, der er fået kontrol over eksem. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	22.400	<b>28.000</b>
<p><b>Mental sundhed: Når eksem breder sig til sindet</b> Mental sundhed spiller en stor rolle, når man lever med eksem. Artiklen fokuserer på, hvordan følelser og hud hænger sammen og giver råd til håndtering af de svære tanker og frustrationer. Deler også foreningens relevante eksisterende patientfilm. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	22.400	<b>28.000</b>
<p><b>Dos &amp; dnts</b> Tips og råd fra andre patienter, foreningen og sundhedsfaglig om, hvad man selv kan gøre for at dulme eksem og kløe udover den medicinske behandling. Og hvad man kan gøre – og ikke skal gøre – for at passe på sin hud. Også fokus på gode vaner. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	23.600	<b>29.500</b>
<p><b>Fakta og myter om eksem</b> Afmontering af myter som fx at man kan spise sig fra eksem. Artiklen understreger, at behandling er nødvendig og vejen til et (næsten) eksemfrit liv. Inkl. sundhedsfaglig validering, indkøb af foto, design af relevante ikoner og opsætning.</p>	24.800	<b>31.000</b>
<p><b>Pårørende</b> Tips til pårørende om, hvordan de kan hjælpe den eksemramte med alt fra indsmøring til en forståelse af, at man ikke lige kan lade være med at klø. Deler også foreningens video med pårørende. Inkl. sundhedsfaglig validering, indkøb af foto og opsætning.</p>	21.200	<b>26.500</b>
<p><b>Manifest: Eksem på den politiske agenda</b> Fokus på foreningens mærkesager og hvad foreningen kæmper for politisk. Som et slags manifest, som foreningen kan bruge i dialogen med politikere og beslutningstagere. Ligger på hjemmesiden og kan printes til møder. Inkl. udvikling af grafisk element og opsætning.</p>	24.800	<b>31.000</b>

### Eksemtest

Online test, der skal empower eksempatienter til at tage dialogen med (hud)lægen og insistere på en behandlingsplan, der kan føre dem frem til et (næsten) eksemfrit liv. Testens indhold udvikles i samarbejde med og valideres af relevant sundhedsfaglig person.

<b>Eksemtest</b>	<b>EX moms</b>	<b>Inkl. moms</b>
<b>Test dig selv: Kan du få mindre eksem og kløe?</b> Online test, der gennem få spørgsmål giver en indikation af, om man har kontrol over sit eksem – eller kan få det bedre. Spørgsmålene udvikles i samarbejde med sundhedsperson.  Eksemtesten udvikles med et banner på forsiden og en selvstændig underside, der linker ind til testen. Inkl. ide, visuelt koncept og design, udvikling af testens spørgsmål og uddannende bonusinfo for at give modtageren en bedre forståelse af eksem og behandling. Hertil kodning, opsætning og kvalitetstjek af testen.	139.840	<b>174.800</b>

### Lancering

Udbredelse af opmærksomhed og trafik til artikler og test.

<b>Lancering</b>	<b>EX moms</b>	<b>Inkl. moms</b>
<b>Lancering: Opfølgende og uddannende email-program</b> Udvikling af emailflow, der i tre mails skal empower patienter til at søge lægehjælp ved symptomer. Den første mail udsendes umiddelbart efter endt test og følger op på testens resultater. De følgende mails fastholder opmærksomheden, uddanner patienterne og klæder dem på til dialogen med lægen.	86.980	<b>108.725</b>
<b>Lancering: Social Media kampagne over 2 måneder</b> Ca. 2 måneders push til test. Data fra kampagnen giver indsigt i, hvor mange der er velbehandlede – og ikke er det. Vi forventer, at kampagnen vil få mindst 3000 til at gennemføre testen.  Kampagnen inkluderer strategi, visuelt koncept, contentplan, copywriting, udvikling af grafik og animationer til både feed og reels på Facebook og Instagram. Hertil målgruppesegmentering, opsætning i abc-test, løbende optimering og annoncebudget på i alt	124.360	<b>155.450</b>

30.000 dkk. Afsluttende afrapportering inkl. bearbejdning af data ift. fordeling mellem velbehandlet/ikke-velbehandlet.		
---	--	--

# DK AD Patient empowerment

Endelig revisionsrapport


2025-11-26

Oprettet:	2025-11-26
Af:	Kristin Fauskrud (KNFNO@LEO-PHARMA.COM)
Status:	Underskrevet
Transaktions-id:	CBJCHBCAABAAqfLr7Jo5FWcDaJMBaexAx3DKdFP1uq3K

## Oversigt over "DK AD Patient empowerment"

 Dokument oprettet af Kristin Fauskrud (KNFNO@LEO-PHARMA.COM)


2025-11-26 - 09:01:41 GMT- IP-adresse: 80.203.116.211

 Dokumentet blev sendt til Anne Vastrup (anne@vastrup.dk) til underskrivelse

2025-11-26 - 09:03:01 GMT


 E-mail blev vist af Anne Vastrup (anne@vastrup.dk)

2025-11-26 - 10:57:18 GMT- IP-adresse: 188.177.121.21

 Anne Vastrup (anne@vastrup.dk) godkendte med Adobe Acrobat Sign.


Udfordring: Brugeren åbnede aftalen.

2025-11-26 - 10:57:36 GMT

 Anne Vastrup (anne@vastrup.dk) godkendte med Adobe Acrobat Sign.

Udfordring: Brugeren fuldførte underskrivelsesceremonien.

2025-11-26 - 11:00:26 GMT

 Dokumentet blev underskrevet digitalt af Anne Skov Vastrup (anne@vastrup.dk)

Årsag til underskrivelse: Accepteret og Enig

Udbyder af skytjeneste: MitID

Certifikatudsteder: Intesi Group Advanced Cloud Signature Short Term CA

Sikkert tidsstempel: 2025-11-26 - 11:00:29 GMT

Tidsstempelleverandør: Adobe Qualified Timestamp TSU8

Underskrivers IP-adresse: 188.177.121.21

 Dokumentet blev sendt til Anja Verhaug (AVENO@LEO-PHARMA.COM) til underskrivelse

2025-11-26 - 11:00:30 GMT

 E-mail blev vist af Anja Verhaug (AVENO@LEO-PHARMA.COM)

2025-11-26 - 11:49:13 GMT- IP-adresse: 104.47.51.190



Powered by  
**Adobe**  
Acrobat Sign

✔ Anja Verhaug (AVENO@LEO-PHARMA.COM) godkendte med Adobe Acrobat Sign.

Udfordring: Brugeren åbnede aftalen.

2025-11-26 - 11:49:46 GMT

✔ Anja Verhaug (AVENO@LEO-PHARMA.COM) godkendte med Adobe Acrobat Sign.

Udfordring: Brugeren fuldførte underskrivelsesceremonien.

2025-11-26 - 11:50:53 GMT

📄 Dokumentet blev underskrevet digitalt af Verhaug, Anja Cecilie (AVENO@LEO-PHARMA.COM)

Årsag til underskrivelse: Accepteret og Enig

Udbyder af skytjeneste: BankID Norway

Certifikatudsteder: Intesi Group Advanced Cloud Signature Short Term CA

Sikkert tidsstempel: 2025-11-26 - 11:50:56 GMT

Tidsstempelleverandør: Adobe Qualified Timestamp TSU8

Underskrivers IP-adresse: 62.84.222.42

✔ Aftale fuldført.

2025-11-26 - 11:50:55 GMT

